IGM Biosciences News

H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12

H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.4%

moomoo News06:32 ET

IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones06:31 ET

Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data

TipRanks06:26 ET

Express News | HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target

Benzinga06:22 ET

Jefferies Maintains IGM Biosciences(IGMS.US) With Buy Rating, Maintains Target Price $48

Jefferies analyst Roger Song maintains $IGM Biosciences(IGMS.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 31.7% and a tot

moomoo NewsMay 23 09:31 ET

IGM Biosciences IGMS +36% Acquisition Rumors; Biodexa BDRX -45% Warrants Exercise

BioPharmCatalystMay 22 16:36 ET

12 Health Care Stocks Moving In Wednesday's Intraday Session

GainersIGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDA

BenzingaMay 22 12:31 ET

IGM Biosciences up 40% Following Biogen HI-Bio Buy

Seeking AlphaMay 22 11:44 ET

CureVac, Oragenics, IGM Biosciences Among Healthcare Movers

Seeking AlphaMay 22 10:00 ET

Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.

BenzingaMay 20 13:28 ET

IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Clinical ...

Yahoo FinanceMay 10 14:38 ET

Express News | Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target

BenzingaMay 9 08:49 ET

IGM Biosciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 119.3% Wedbush → $20 Reiterates Outperform → Outperform 04/18/2024 31.58% HC Wainwright & Co. →

BenzingaMay 9 08:47 ET

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)

TipRanksMay 9 08:20 ET

Express News | IGM Biosciences Inc : RBC Cuts Target Price to $20 From $21

ReutersMay 9 02:18 ET

IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p

BenzingaMay 8 18:10 ET

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

Yahoo FinanceMay 8 17:55 ET

Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000

04:42 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000

MT NewswiresMay 8 16:42 ET

Express News | IGM Biosciences Inc - Expects to End 2024 With Balance of $180 Million in Cash and Investments

ReutersMay 8 16:14 ET

Express News | IGM Biosciences - as a Result of Refocusing of Sanofi Collaboration Announced in April, Expects to Recognize FY Collaboration Revenue of $63 Mln

ReutersMay 8 16:14 ET